<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646503</url>
  </required_header>
  <id_info>
    <org_study_id>CLDT600ACN04</org_study_id>
    <nct_id>NCT00646503</nct_id>
  </id_info>
  <brief_title>Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B</brief_title>
  <official_title>A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End of Year 4 Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients experiencing serious adverse events (for all SAEs, and SAEs attributed to study drug). Proportion of patients experiencing adverse events, coded by body system ( all AEs, and AEs attributed to study drug).</measure>
    <time_frame>At Baseline, Week 24 and Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>For HBeAg-positive patients, Maintained Virologic Response, here defined as HBeAg loss and serum HBV DNA PCR negative (COBAS Amplicor PCR &lt; 300 copies/ml) during the whole study period.</measure>
    <time_frame>At Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg/day, oral telbivudine for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>600 mg/day, oral telbivudine for 52 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SEBIVO</other_name>
    <other_name>TYZEKA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patient completed Omnibus study and will be available to immediately rollover into
             this study without discontinuation of study drug.

          -  Patient was not discontinued from the previous Omnibus study.

          -  Male or female, adult patients with CHB (HBeAg positive or HBeAg negative).

          -  Patient is willing and able to provide written informed consent to participate in the
             study.

          -  HBV DNA PCR undetectable in recent 12 months.

        Exclusion criteria

          -  Pregnant or breastfeeding, or has plan of pregnant during study period.

          -  Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), r HIV at
             screening visit.

          -  Patient needs any anti-HBV treatment combination (add-on therapy) or switch to other
             anti HBV treatment from Telbivudine at investigator's discretion.

          -  Patient has any laboratory value abnormality that physicians think he/she may not be
             suitable to continue the Telbivudine treatment.

          -  Patient has any clinically significant concurrent severe or unstable disease
             conditions that physicians think he/she may have any additional risk or not be
             suitable to participate the study.

          -  Patient has evidence of renal insufficiency defined as patient requiring dialysis or
             having an estimated creatinine clearance below 50mL/min, as estimated by the
             cockcroft-Gault formula.

          -  Patient is currently abusing alcohol or illicit drugs.

          -  Patient is enrolled or plans to enroll in another clinical trial of an investigational
             agent while participating in this study.

          -  All other treatments for hepatitis B, including commercially available treatments
             indicated for conditions other than chronic hepatitis B that are being investigated to
             treat or may have activity against HBV (e.g., ribavirin, famciclovir, ganciclovir,
             etc.)

          -  Prolonged use of systemic acyclovir or famciclovir defined as episodic treatment with
             these agents for periods exceeding 10 days every 3 months, or chronic suppressive
             therapy.

          -  Systemic immunomodulators of any type.

          -  Systemic corticosteroids ( topical and inhaled corticosteroids are permitted).

          -  Herbal medications known to cause hepatotoxicity (e.g., St. John's Wart, Kava, Jin Bu
             Huan, Yuzhitang, germander, chaparral, shark cartilage, mistletoe, slim 10,
             Lipokinetix, etc.).

          -  Patient has any of the following laboratory values:

               -  Hemoglobin &lt; 9 g/dL for menor &lt;8 g/dL for women.

               -  Total WBC &lt;1,500/mm3

               -  Absolute neutrophil count (ANC)&lt;1,000/mm3

               -  Platelet count &lt;30,000/mm3

               -  Serum albumin &lt;2.5g/dL

               -  Total bilirubin ≥4×ULN

               -  Serum creatinine &gt;1.5×ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=5764</url>
    <description>Results for CLDT600ACN04 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Adv Ther. 2015 Aug;32(8):727-41. doi: 10.1007/s12325-015-0232-2. Epub 2015 Sep 2.</citation>
    <PMID>26329749</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B, Chronic</keyword>
  <keyword>Telbivudine</keyword>
  <keyword>Polymerase Chain reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

